These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 17508024

  • 1. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
    Thallinger C, Werzowa J, Poeppl W, Kovar FM, Pratscher B, Valent P, Quehenberger P, Joukhadar C.
    J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.
    Thallinger C, Poeppl W, Pratscher B, Mayerhofer M, Valent P, Tappeiner G, Joukhadar C.
    Pharmacology; 2007 Oct; 79(4):207-13. PubMed ID: 17377418
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.
    Valero T, Steele S, Neumüller K, Bracher A, Niederleithner H, Pehamberger H, Petzelbauer P, Loewe R.
    J Invest Dermatol; 2010 Apr; 130(4):1087-94. PubMed ID: 19940857
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR.
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [Abstract] [Full Text] [Related]

  • 10. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
    Hillner BE, Agarwala S, Middleton MR.
    J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
    [Abstract] [Full Text] [Related]

  • 11. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
    Busch C, Geisler J, Lillehaug JR, Lønning PE.
    Eur J Cancer; 2010 Jul; 46(11):2127-33. PubMed ID: 20541396
    [Abstract] [Full Text] [Related]

  • 12. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
    Huncharek M, Caubet JF, McGarry R.
    Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
    [Abstract] [Full Text] [Related]

  • 13. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
    Van Dyk JJ, Falkson G.
    Med Pediatr Oncol; 1975 Feb; 1(2):107-11. PubMed ID: 1228411
    [Abstract] [Full Text] [Related]

  • 14. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
    Hardy KM, Strizzi L, Margaryan NV, Gupta K, Murphy GF, Scolyer RA, Hendrix MJ.
    Mol Cancer Res; 2015 Apr; 13(4):670-80. PubMed ID: 25767211
    [Abstract] [Full Text] [Related]

  • 15. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y.
    J Clin Oncol; 2004 Mar 15; 22(6):1118-25. PubMed ID: 15020614
    [Abstract] [Full Text] [Related]

  • 16. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
    Sadhu SS, Wang S, Averineni RK, Seefeldt T, Yang Y, Guan X.
    Melanoma Res; 2016 Dec 15; 26(6):572-579. PubMed ID: 27540834
    [Abstract] [Full Text] [Related]

  • 17. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
    Revskaya E, Jongco AM, Sellers RS, Howell RC, Koba W, Guimaraes AJ, Nosanchuk JD, Casadevall A, Dadachova E.
    Clin Cancer Res; 2009 Apr 01; 15(7):2373-9. PubMed ID: 19293257
    [Abstract] [Full Text] [Related]

  • 18. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine.
    Singh S, Davis R, Alamanda V, Pireddu R, Pernazza D, Sebti S, Lawrence N, Chellappan S.
    Mol Cancer Ther; 2010 Dec 01; 9(12):3330-41. PubMed ID: 21139044
    [Abstract] [Full Text] [Related]

  • 19. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z, Strojan P.
    Neoplasma; 1996 Dec 01; 43(2):93-7. PubMed ID: 8843969
    [Abstract] [Full Text] [Related]

  • 20. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
    Kiebert GM, Jonas DL, Middleton MR.
    Cancer Invest; 2003 Dec 01; 21(6):821-9. PubMed ID: 14735685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.